Using scientific publications strategy to ensure a pharmaceutical company’s credibility and a product’s viability.
Scientific publications remain the principal way that biopharmaceutical organizations relay critical clinical trial data to key external stakeholders such as physicians and payers. Data from different phases of drug development are the earliest ways these stakeholders learn about new products and the information serves as the building blocks for how a new product will be positioned in the marketplace.
With growing calls for transparency and data disclosure, global publications leaders find themselves in a balancing act—ensuring both scientific credibility and commercial viability. To help publications leaders navigate this emerging landscape, research and consulting leader Best Practices, LLC undertook benchmarking research to investigate how top pharmaceutical and biotechnology companies shape their global scientific publication strategies to maintain credibility in the scientific community and deliver publications that drive brand success.
The study found that open access platforms are gaining popularity for publication processes; 44 percent of companies in the study believe such platforms will impact publication strategy going forward. Part of the allure for open access platforms is they make information readily available to physicians and patients alike. In the wake of open access platforms, companies foresee an impact on areas such as journal selection, publication approval and delivery, and speed of data disclosure.
For this study, Best Practices, LLC engaged 20 leaders from 19 biopharmaceutical companies through a benchmarking survey and executive interviews.